How different ways of defining iron deficiency (ID) impact the prevalence estimates of this common disorder among women.
J&J psoriasis drug licensed from Protagonist doesn’t top competition in Phase IIb trial
Johnson & Johnson’s oral IL-23 that it licensed from Protagonist Therapeutics appears to be a weaker psoriasis treatment than some of its injectable competition, according